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Audiovestibular Dysfunction and 
Hearing Loss in Patients with 
Psoriasis and Psoriatic Arthritis
Sevgi Akarsu
Abstract
Psoriasis is now considered a T cell-mediated chronic systemic inflammatory 
disease rather than only a simple skin disease. The relationship and coexistence 
of this common disease with many other comorbidities have gained increasing 
attention in recent years. Although psoriatic skin lesions are seen frequently in 
the auricle and external auditory canal, there are not many studies evaluating the 
possible effect of psoriatic disease (psoriasis with or without joint involvement) on 
the auditory system. Hearing impairment detected in psoriasis patients is mostly 
seen as subclinical hearing loss at high frequencies, but it can also have a significant 
impact on patients’ health and quality of life due to the possible risk of develop-
ing sudden sensorineural hearing loss. In this chapter, the frequency, pattern, and 
patient-related risk factors of hearing impairment and audiovestibular dysfunction 
in patients with psoriasis and psoriatic arthritis were extensively reviewed and 
discussed. In conclusion, it was emphasized that subclinical sensorineural hear-
ing loss is a neglected but an important comorbidity in patients with psoriasis and 
psoriatic arthritis. The relationship between psoriatic disease and audiovestibular 
dysfunction supports the need for further studies aimed at better identification of 
the underlying pathogenic mechanisms, and accordingly to update diagnostic and 
even treatment approaches.
Keywords: psoriasis, psoriatic arthritis, hearing impairment, sensorineural hearing 
loss, deafness, audiovestibular dysfunction
1. Introduction
Psoriasis is a common erythemato-squamous disease which has a prevalence 
of 2–4% in the general population [1, 2]. Even though the precise etiology remains 
unknown, it is now considered an autoimmune, chronic, immune-mediated 
inflammatory disease (IMID) characterized by T cell mediated hyperproliferation 
of keratinocytes [3, 4]. There are multiple clinical types of psoriasis that can overlap 
in a spectrum from mild sebopsoriasis localized to the scalp to generalized pustular 
psoriasis. In the most common type of psoriasis vulgaris, the diameters of erythe-
mato-squamous papular lesions can range from pinhead-size to plaques covering 
the larger skin surface. Besides typical skin involvement in psoriasis, significant 
deterioration of the nails and painful inflammatory joint involvement (psoriatic 
arthritis, PsA) can also be seen [1, 2]. PsA is a disease in the group of seronegative 
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spondyloarthropathies, such as ankylosing spondylitis and reactive arthritis. While 
its prevalence in the general population has been estimated between 0.02% and 
0.42%, its frequency in people with psoriasis ranges from 6–42%. This inflamma-
tory arthritis has different symptoms such as pain, swelling or stiffness and sausage 
digits (dactylitis) in one or more joints, Achilles tendinitis or plantar fasciitis. 
Psoriasis and PsA have been considered by some clinicians as different diseases due 
to various diagnostic criteria and different clinical courses, but the relationship 
between both diseases cannot be ignored [5–7]. It is well known that psoriatic dis-
ease with or without arthritis can occur at any age and negatively affects the quality 
of life by disrupting lifelong physical and psychosocial health [8, 9].
External ear involvement is also common in psoriasis [10]. Approximately 
two-thirds of patients have typical psoriatic lesions characterized by itchy, well-
demarcated, erythemato-squamous plaques on the earlobe and conchal bowl. 
Although non-specific erythematous, scaly and dry lesions are sometimes seen in 
the ear, the precise diagnosis of ear psoriasis can be made easily by detecting typical 
psoriatic lesions in other areas of the body [2, 11]. Despite the high prevalence of 
clinical lesions affecting the auricle and the external auditory canal in psoriasis, 
there are not many studies evaluating the possible effect of psoriatic disease on the 
auditory system [12–25]. The auricle and outer one-third of the external auditory 
canal contain elastic cartilage covered with skin and its appendages, including 
mainly hair cells, and sebaceous and apocrine glands. It has been reported that 
chronic cutaneous inflammation and keratinocyte hyperproliferation induce 
progressive skin thickening with the tendency of substenosis and serum accumula-
tion in the external auditory canal and stenosis of the tympanic membrane, causing 
disruption in sound transmission to the middle ear [22]. It is also well known that 
otitis externa is frequently seen in infection-prone conditions such as psoriasis 
[10]. Moreover, the rare ototoxic effect of topical salicylic acid, which is among the 
antipsoriatic topical treatments, was reported in a few cases. Maune et al. observed 
recurrent, symmetrical, pancochlear, reversible inner ear failure in a psoriasis 
patient using topical salicylate [26]. However, for the first time in 2004, sudden-
onset autoimmune sensorineural hearing loss (SNHL) was reported in two cases 
with PsA [27, 28]. Yen et al. evaluated the risk of sudden SNHL in patients with 
psoriasis in a retrospective cohort study involving 28.817 patients and gender-, age-, 
and comorbidities-matched controls. The incidence of sudden SNHL was found 
about 1.51 times higher in the psoriasis cohort after 6 years of follow-up than in the 
control cohort [12].
In previous studies, it has been mentioned that the inner ear is sensitive to 
local or systemic autoimmune attacks and SNHL can occur as a complication of 
non-organ-specific autoimmune diseases [29–32]. The hypothesis that SNHL 
may develop as a result of an autoimmune process against the inner ear was first 
introduced by Lehnhardt in 1958 [33]. 20 years later (1979), McCabe was the first to 
describe SNHL that may occur in the autoimmune diseases. The idea was suggested 
by the author that an autoimmune pathogenesis may be present in the etiology upon 
improvement of hearing after corticosteroid therapy in a patient with progres-
sive bilateral idiopathic SNHL [34]. Since then, several cases of SNHL and acute/
subclinical audiovestibular dysfunction accompanied by various autoimmune and 
autoinflammatory diseases including vitiligo, inflammatory bowel disease (e.g., 
Crohn’s disease, ulcerative colitis), Behçet’s disease, Wegener’s granulomatosis, 
rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, relapsing 
polychondritis, giant cell arteritis, ankylosing spondylitis, Vogt-Koyanagi-Harada 
syndrome, Cogan’s syndrome and Susac’s syndrome, have been reported in the 
literature [29, 35, 36]. Current literature information shows that SNHL is the most 
common auditory symptom of systemic autoimmune diseases, but due to the 
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different presentations (sudden or progressive) and severity (mild or severe) of 
SNHL, early correlation between symptom and systemic autoimmune disease may 
be difficult [29]. Additionally, audiovestibular symptoms found in autoimmune 
conditions are also common in other disorders, such as diabetes and hypertension. 
For these reasons, the correct differential diagnosis of the cause of audiovestibular 
involvement is very important [30, 31].
Although autoimmunity has been accused of sudden hearing loss for many 
years, interest in studies related to the inner ear involvement secondary to systemic 
autoimmune diseases has been gradually increasing in recent years [30, 35]. In 
the literature about psoriatic disease-related hearing loss, firstly, Srikumar et al. 
reported a 62-year-old male patient with PsA, who had been under methotrexate 
therapy, developed sudden onset of SNHL and recovered with oral corticosteroids. 
So that, it was suggested by the author that PsA should have added to autoimmune 
diseases that can cause SNHL [27]. Subsequently, Giani et al. reported the develop-
ment of bilateral asymmetric sensorineural deafness, which improved with oral 
prednisolone without interruption of previous etanercept therapy, in a 13-year-old 
girl with juvenile PsA [28]. However, after these case reports, a limited number of 
studies evaluating hearing and/or the audiovestibular system were conducted to 
determine whether the chronic inflammatory process and/or autoimmunity affect 
the inner ear in psoriasis patients with or without joint involvement [12–25].
In this chapter, case reports, clinical trials, cohort studies, systematic reviews 
and meta-analyses associated with hearing impairment and audiovestibular dys-
function in patients with psoriasis and PsA published up until now were compre-
hensively reviewed and discussed. The Medline literature database was searched 
through PubMed using the keywords, individually and in combination: ‘psoriasis’, 
‘psoriatic arthritis’, ‘hearing loss’, ‘sensorineural hearing loss’, ‘deafness’, ‘hearing 
impairment’ and ‘audiovestibular dysfunction’. Only articles available in original or 
translated English were evaluated.
2.  Audiological/audiovestibular evaluations in patients with psoriasis/
psoriatic arthritis
When all clinical studies are reviewed, it has been observed that psoriasis/
PsA patients and the control group consisting of volunteer healthy subjects were 
compared with each other in terms of audiological changes [12–25]. In just a few 
studies, these groups were also evaluated in terms of the accompanying vestibular 
system involvement [15, 20, 21, 25]. Comprehensive ear, nose and throat examina-
tions were performed by otorhinolaryngologists in all cases before audiological 
evaluations. Subsequently, pure tone audiometric and otoacoustic emission (dis-
tortion product or transient evoked) tests, as well vestibular tests in some studies 
were applied by audiometrists (Table 1). Generally, cases with the current and/
or past history of chronic otitis externa, recurrent otitis media, inner ear infec-
tions, otosclerosis, suppurative labyrinthitis, Meniere disease and other vestibular 
syndromes, congenital ear disease, ear membrane perforation, ear surgery, 
head and neck trauma, exposure to high-decibel levels, cardiovascular disease 
(ischemic heart disease including angina, myocardial infarction, heart failure), 
cerebrovascular events (transient ischemic attacks/strokes confirmed by MRI/CT 
brain scan), peripheral arterial disease confirmed by Doppler ultrasound and/or 
arteriography, renal insufficiency, vertigo, any ototoxic drug use (e.g., quinolones, 
macrolides, aminoglycosides, antidepressants, beta blockers, hormone antagonists, 
antiglaucoma preparations, antimalarials), flat tympanogram and hearing aid use 
were not included in these studies. It was observed that current and/or past use of 
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References Study cases Audiological/audiovestibular diagnostic tests
[13] 42 PSO patients, 
60 healthy controls
Pure tone audiometry (0.25, 0.5, 1, 2, 4, 6 kHz)
Tympanometry, Acoustic reflex
Distortion product otoacoustic emission testing
[14] 51 PSO patients, 
51 healthy controls
Pure tone audiometry
[15] 60 PsA patients,
60 matched 
controls
Pure tone audiometry (0.5, 1, 2, 3, 4, 6, 8 kHz)
Speech discrimination test, tympanometry, stapedius reflex 
threshold
MRI of the posterior fossa and brainstem
Videonystagmography testing device
Spontaneous nystagmus, gaze-evoked nystagmus, oculocephalic 
response, head-shaking nystagmus
Oculographic tests (saccades; slow, smooth pursuit evaluation; and 
optokinetic stimulus)
Positional nystagmus in supine, lying on the right, lying on the left, 
and cervical hyperextension positions (head hanging)
Cephalic rotational test in the supine position; Dix-Hallpike test
Quantitative postural function test
Bithermal water caloric test
[16] 31 PsA patients, 
31 healthy controls
Pure tone audiometry (0.25, 0.5, 1, 2, 4, 6 kHz)
Speech discrimination score, tympanometry
Transient evoked otoacoustic emissions
[17] 41 PSO patients, 
41 healthy controls
Pure tone audiometry (air-conduction at 0.25, 0.5, 1, 2, 4, 8 kHz; 
bone-conduction at 0.5, 1, 2, 4 kHz)
Transient evoked otoacoustic emissions
[18] 24 PsA patients, 
38 healthy controls
Distortion product otoacoustic emissions (1–4 kHz)
Tympanometric examination
Stapes reflex values, speech reception threshold
Speech discrimination values
Pure tone values (0.25 kHz – 8 kHz)
High-frequency values (10, 12.5, 16 kHz)
[19] 50 PSO patients, 
45 healthy controls
Pure tone audiogram (0.5 kHz −16 kHz)
Speech audiometry
[20] 60 PsA patients, 
60 matched 
controls
Clinical test of sensory integration and balance Computerized 
dynamic posturography
[21] 61 PSO patients, 
61 healthy controls
Pure tone audiometry (0.25–1 kHz, 2–6 kHz), autoacoustic 
emission, stapes reflex, detection threshold of speech 
- discrimination
Electronystagmography tests; spontaneous nystagmus, gaze-evoked 
nystagmus, oculographic tests (saccades; slow, smooth pursuit 
evaluation; optokinetic stimulus)
Positional nystagmus in supine, lying on the right, lying on the left, 
cervical hyperextension positions (head hanging)
Cephalic rotational test in the supine position
Dix-Hallpike test, Bi-thermal water caloric test
[22] 77 PSO patients, 
77 healthy controls
Tympanometry
Audiometric tests
[23] 29 PSO patients,
30 healthy controls
Tympanography
Pure tone audiometry (0.25, 0.5, 1, 2, 4, 8, 10, 12, 14, 16 kHz)
Speech audiometry, impedance audiometry
Transient evoked otoacoustic emissions
Distortion product otoacoustic emissions
[24] 50 PSO patients, 
50 healthy controls
Pure tone audiometry (0.25, 0.5, 1, 2, 4, 8 kHz)
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non-steroidal anti-inflammatory drugs, prednisone, methotrexate and/or tumor 
necrosis factor-α (TNF-α) antagonists were present in all patients with PsA and 
in some psoriasis patients. To evaluate the clinical severity of psoriatic disease, 
mostly Psoriasis Area and Severity Index (PASI) was used. In addition to PASI, body 
surface area, investigator’s global assessment and dermatology life quality index 
were applied in a few studies [13–25]. The results of these studies are summarized 
below in chronological order.
Firstly, Karabulut et al. (2010) did not find a statistically significant difference 
between each groups for either pure tone audiometric hearing thresholds or distor-
tion product autoacustic emissions in a case-control study involving 42 patients 
with psoriasis. In addition, neither SNHL nor any damage of outer hair cells of 
cochlea was detected. The authors suggested that the increase in the frequency of 
hearing loss and vestibular disorders in chronic inflammatory and autoimmune 
diseases may be due to the more prominent role of CD4 T cells rather than the 
predominant CD8 T cells in psoriasis [13].
In 2012, Guvenc et al.’s study (involving 51 psoriasis patients, 51 controls) 
demonstrated that the hearing threshold values at all frequencies for air conduc-
tion and bone conduction in psoriasis patients were significantly higher than in the 
control group with the pure tone audiometry measurements. Statistical significance 
was achieved in all frequencies (more pronounced at higher frequencies) except to 
right ear air conduction 1000 Hz, bone conduction 500 and 1000 Hz, as well left ear 
air conduction 500 Hz and bone conduction 500 Hz measurements. No significant 
relationship was found in the correlation analysis between age and psoriasis dura-
tion and hearing loss. When the PASI score adjusted for age and disease duration 
and threshold values matching the frequencies were compared with the correlation 
analysis, a significant correlation was found between the PASI score and hearing 
loss at medium and high frequencies. The fact that the hearing loss detected was 
independent of age and disease duration suggested to the authors that hearing 
loss in psoriasis is not an age-related degeneration and is not due to the long-term 
low-level effect of inflammatory mediators. Due to the statistically significant and 
moderately correlation between hearing loss at medium and high frequencies (bone 
conduction 2000, 4000 Hz; air conduction 1000, 2000, 4000, 8000 Hz) and high 
PASI scores, the authors considered that hearing loss is occurred as a consequence 
of increasing proinflammatory cytokines such as TNF-α (which is responsible 
for the severity of the psoriatic disease) in exacerbation periods of psoriasis and 
subsequently causing cochlear degeneration [14].
A case-control study of 60 PsA patients by Amor-Dorado et al. (2014) demon-
strated that the frequencies of tinnitus, vertigo and disequilibrium as well as the 
subjective hearing loss (31.7% of PsA vs. 6.7% of controls) were significantly higher 
in the PsA group. Patients with PsA exhibited significantly higher values of pure 
tone audiogram and speech reception threshold than controls. Abnormal hearing 
References Study cases Audiological/audiovestibular diagnostic tests
[25] 32 PSO patients
(−) arthritis,
35 healthy controls
Pure tone audiometry (0.25, 0.5, 1, 2, 4, 6, 8 kHz)
Distortion product otoacoustic emission (2,3,4,5 kHz)
Spontaneous and gaze-evoked nystagmus
Head shake test, tandem stance test, Unterberger test, Romberg test, 
Dix-Hallpike test, supine roll test, head hanging test
Oculomotor and caloric tests
PSO (Psoriasis); PsA (Psoriatic Arthritis).
Table 1. 
Audiological/audiovestibular diagnostic tests in patients with psoriasis/psoriatic arthritis.
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loss in the audiogram (60% vs. 8.3%), bilateral and symmetrical SNHL predomi-
nant at high frequencies (46.7% vs. 8.3%), abnormal vestibular tests, abnormal 
oculocephalic response (13.3% vs. 0%), abnormal caloric test (26.7% vs. 0%) and 
abnormal computerized dynamic posturography with a predominant vestibular loss 
pattern (23.3% vs. 0%) frequencies were significantly higher in the PsA group than 
in the control group. No significant relationship was found between the presence of 
audiovestibular symptoms in patients with PsA and the specific patterns, diagnosis 
age and disease duration of PsA. This study was the first to show oculographic, ves-
tibular, and postural abnormalities in addition to auditory impairment in psoriatic 
disease. These tests, which show the presence of hypofunction (canal paresis) of 
the inner ear, supported that the audiovestibular distortion observed in PsA is at the 
peripheral etiology and the inner ear damage is at the cochleovestibular peripheral 
level. It has also been suggested that chronic inflammation may be responsible for 
audiovestibular findings in patients with PsA [15].
Akdag et al. (2015) investigated hearing changes with audiometric and oto-
acoustic emission tests in the age-gender matched prospective case-control study 
involving 31 PsA patients. As a result of the study, statistically significant differ-
ences (especially at high frequencies) were observed between pure tone audiometry 
in all frequencies and right and left emission at the 4.0 and 1.0 Hz in PsA patients 
versus controls. No significant relationship was found between the duration of PsA 
and the severity of hearing loss. Except for right ear audio at 2000 Hz, no correla-
tion was found between the PASI measurement of PsA severity and hearing loss. In 
addition, no significant relationship was found between PASI scores and the degree 
of hearing changes. These data showed to the authors that the degree of hearing 
change was not related to the severity of PsA symptoms. Overall, mean hearing 
thresholds and otoacoustic emissions were detected to be impaired in PsA patients. 
With these results, it was thought that the inner ear injury is due to cochlear chronic 
damage caused by disruption of the inner ear microcirculation rather than acute 
inflammatory reactivation of the disease [16].
Aydın et al.’s study (2015) did not find any hearing loss with pure tone audiom-
etry and transient evoked autoacoustic emission measurements in 41 patients with 
mild and moderate psoriasis. Hearing thresholds in all frequencies with pure tone 
audiometry were detected higher in patients with psoriasis than controls. Although 
the excitability, response values and signal:noise ratios according to frequencies 
were lower in the transient evoked autoacoustic emission test compared to the con-
trols, these differences were not statistically significant. In addition, a relationship 
was not demonstrated between PASI score and psoriasis duration and SNHL [17].
In 2016, a case-control study involving 24 PsA patients (younger than 60 years 
old) conducted by Gunes et al. demonstrated bilateral symmetrical SNHL in 3 
patients within the PsA group. When hearing frequencies between 4000 and 
6000 Hz and the distortion product otoacoustic emission values at 3000 and 
4000 Hz were evaluated in the PsA group, statistically significant differences 
were found compared to the control group. This study demonstrating that inner 
ear functions have been affected in patients with PsA provides strong evidence 
that it is necessary to monitor these patients regarding SNHL, which may cause 
serious disability, in order to take precautions against the development of sudden 
 deafness [18].
Hapa et al. (2016) found significant differences between patients with psoriasis 
and controls in terms of median pure tone averages variables in a case-control 
study involving 50 psoriasis patients. However, no significant differences were 
observed between median pure tone averages variables according to the distribu-
tion of the lesions, previous systemic medications, disease duration and PASI 
scores. Considering the hearing levels of patients with psoriasis according to certain 
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hearing frequencies (500, 1000, 2000, 4000, 8000 and 16,000 Hz), a statistically 
significant difference was detected between patients with psoriasis and the control 
group. It was determined that all the frequencies which show statistical significance 
(the median of hearing level at frequencies 500–4000 Hz) were not lower than 20 
decibels, but the hearing levels of patients with psoriasis at higher frequencies (such 
as 8000 and 16,000 Hz) were lower than 20 decibels. This result indicated to the 
authors that psoriasis patients have hearing loss at high frequencies [19].
Amor-Dorado et al.’s vestibular evaluation study (2017) involving 60 PsA 
patients observed that the frequencies of abnormal oculocephalic response (13.3% 
vs. 0%) and abnormal caloric test (26.7% vs. 0%) were found higher than the con-
trols. The frequencies of abnormal clinical test of sensory integration and balance 
test with vestibular loss pattern (33% vs. 6%) and abnormal computerized dynamic 
posturography test (23.3% vs. 0%) also increased significantly in PsA patients, 
indicating that oculographic findings have been frequent in PsA [20].
Temel et al.’s study (2017) including 61 psoriasis patients detected significant 
differences between the patients and controls in terms of audiovestibular symptoms 
and the values of the audiometric tests (pure tone average, speech recognition 
threshold, speech discrimination). While psoriasis patients had higher speech 
reception threshold than the control group, the speech discrimination test was 
found to be lower levels. The mean bone conduction and air conduction hearing 
thresholds were observed to be higher for all frequencies in the patients. These 
differences were found to be statistically significant at high frequencies (2.4 and 
6 kHz). According to audiograms, high frequency bilateral symmetrical SNHL was 
detected in psoriasis patients compared to the controls. Although the vestibular 
abnormalities in psoriasis patients were demonstrated to be more common than the 
control group, only saccadic test values were observed to be statistically significant. 
No significant relationship was found between the presence of audiovestibular 
abnormalities and clinical patterns of psoriasis, duration or severity of the disease, 
concomitant PsA, nail involvement or use of anti-psoriatic drugs [21].
In a case-control study involving 77 psoriatic patients of Borgia et al. (2018), 
tympanogram abnormalities and hearing loss detected in the psoriasis group were 
found to be significantly more frequent than the control group (52.6% vs. 14.9%). 
Most of them were shown to had SNHL (SNHL in 57 ears, conductive hearing loss 
in 9 ears, and mixed-type hearing loss in the remaining 15 ears). In terms of hearing 
loss, the difference between both groups was observed to be significant only for 
SNHL. The frequency of hearing loss, mostly of the sensorineural type, increased 
with age at a higher rate in the psoriatic patients. Hearing loss frequency was 
demonstrated to be higher in the patients with psoriasis duration >10 years (mainly 
of conductive and mixed type), metabolic syndrome, higher body mass index levels 
(overweight/obesity) or smoking habit. In patients with arthropathic psoriasis, 
conductive and mixed hearing loss were detected to be more common than non-
arthropathic ones. In addition, it was observed that the patients with hearing loss 
had higher clinical severity of psoriasis determined by PASI and Dermatology Life 
Quality Index scores [22].
In a case-control study involving 29 psoriasis patients, Vir et al. (2019) found 
statistically significant differences between patients and controls for pure tone 
thresholds at high frequencies, and for distortion product otoacoustic emission 
responses and signal:noise ratio at all frequencies. According to these findings, it 
was reported that the outer hair cells damage of cochlea causes high-frequency 
hearing loss in psoriasis patients [23].
In a case-control study including 50 psoriasis patients of Gurel et al. (2019), both 
the left ear and right ear hearing threshold values at 2000 Hz and the right ear hear-
ing threshold values at 4000 and 8000 Hz were significantly higher in the psoriasis 
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group than the control group. It was detected that the values of the psoriasis group 
were statistically significantly higher in terms of both the left ear and right ear mean 
air conduction and bone conduction hearing thresholds. In the correlation analysis 
between PASI score or disease duration and hearing loss, no significant relationship 
was observed [24].
Finally, in a case-control study to evaluate the audiovestibular system in 32 
psoriasis patients without joint involvement, Ertugrul et al. (2020) did not find any 
significant differences between the groups in terms of hearing test results (pure 
tone audiometry and distortion product otoacoustic emission). However, in balance 
tests, the abnormal caloric test response was detected to be significantly higher in 
the psoriatic patients. They also mentioned that the severity of psoriasis rather than 
its duration is more important for vestibular system. No significant association was 
found between the Fitzpatrick skin type, medical treatments, the onset age of or 
clinical pattern of psoriasis and audiovestibular findings [25].
3. Discussion
Since the immunological basis of psoriasis has been understood in recent years, 
it is emphasized that the disease is not limited to the skin but a T cell-mediated 
systemic disease with various chronic and progressive comorbidities [37–42]. Like 
other diseases in this group, many IMIDs can appear in association with psoriasis 
[39–41]. The chronology of IMIDs associated with psoriasis was investigated by 
Andersen et al. in a large-scale study (psoriasis patients = 10.923; general popula-
tion controls = 109.230). It was observed that approximately 20% of the patients 
with psoriasis developed ≥1 IMID, this risk was about five times higher than the 
general population, and most IMIDs had been diagnosed before psoriasis except 
PsA [43]. Many studies have demonstrated that some major comorbidities includ-
ing PsA (mainly associated), metabolic syndrome, diabetes mellitus, coronary 
heart disease, hyperlipidemia, hypertension, obesity, inflammatory bowel disease, 
uveitis, obstructive sleep apnea, non-alcoholic fatty liver disease and psychiatric 
disturbances are more frequent than the normal population as a result of chronic 
inflammation in patients with psoriasis. These observations indicate the necessity 
to investigate for possible morbidities that may accompany psoriasis [39–42]. In 
the IMPROVE (incentives for health care management based on patient-related 
outcomes and value) study conducted in Denmark, it was observed that psoriasis 
has had a significant impact on health care costs, income and employment. In 
addition, psoriasis was also associated with a range of comorbidities (with higher 
incidence of cardiovascular and psychiatric conditions) compared to controls [8]. 
In another study of Baviere et al., it was shown that 30.6% of patients with PsA had 
≥3 comorbidities but the type of comorbidity had more effects than the number of 
comorbidities [9].
Immune-mediated or autoimmune SNHL may be a primary localized disease 
caused by region-specific immune-mediated damage in the inner ear or may be a 
secondary expression of a systemic autoimmune disease. It is characterized by bilat-
eral, asymmetrical, often asynchronous and fluctuant deafness, which clinically 
worsens in weeks or months [29–31]. Tinnitus, dizziness and imbalance can also be 
accompanied [30]. Clinical diagnosis of autoimmune SNHL, mostly seen in women 
and middle age, can be confirmed with a positive response to steroid therapy 
following exclusion of other possible causes [31]. In SNHL accompanying autoim-
mune diseases, inner ear involvement has been observed to be more pronounced at 
high frequency hearing thresholds. Therefore, evaluating the high frequencies of 
the hearing values along with the conventional frequencies in patients who do not 
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identify the clinical symptoms of hearing loss can help detect the presence of early 
hearing impairment and measures against sudden hearing loss can be taken [29–31, 
44]. Extended high-frequency audiometry, expressing sounds above 8000 Hz, has 
been proven as a promising tool for the early detection of hearing disorders [18, 31]. 
In a population-based study using a National Health Insurance Service National 
Sample Cohort data from Korea, Jeong et al. investigated the risk of sudden SNHL 
(commonly known as sudden deafness; a SNHL of 30 dB or more over at least three 
contiguous audiometric frequencies occurring over less than 3 days) in patients 
with autoimmune diseases and compared these findings to a control group. As 
a result of this study, the risk of sudden SNHL was found significantly higher in 
the autoimmune-disease group than in the controls (autoimmune-disease group: 
145/13.250 = 1.09%; control group: 484/6.250 = 0.73%) [45]. Due to unilateral 
involvement in most of the sudden SNHL cases, it may be difficult to demonstrate 
the relationship of this condition with an autoimmune disease. Therefore, it should 
not be ignored that immune-mediated SNHL can rarely occur with unilateral 
involvement in the initial period, similar to sudden SNHL [35, 36].
T lymphocyte-mediated cytotoxicity, vasculitis and immune complex accumula-
tion have been generally accepted as the main causal mechanisms in development 
of SNHL accompanying immune-mediated diseases [29, 32]. Kumar et al. proposed 
a different theory like that “In autoimmune and chronic inflammatory diseases, 
prolonged serum levels of peripherally active T lymphocytes and proinflamma-
tory cytokines (e.g., IL-1, IL-6, TNF-α) may cause degeneration in the cochlea, so 
hearing loss is a result of the harmful and unexpected effects of circulating inflam-
matory mediators”. This model was recommended firstly based on patients with 
ulcerative colitis and was argued to be applicable for other chronic inflammatory 
and autoimmune diseases [46]. Although the cause of psoriasis disease is precisely 
unknown, recent genetic and immunological studies have shown that it is also a 
chronic IMID [38, 39]. Considering that the deteriorations in the structure and 
functions of the skin, nails and joints in psoriasis are primarily related to systemic 
chronic inflammation, it has been suggested that the same pathological process may 
have similar effects on the cochlea and play a role in the development of immune-
mediated hearing loss [37, 47, 48]. T helper (Th) 1, Th17 and Th22 lymphocytes, 
which play a role in the pathogenesis of psoriasis, are active in psoriatic skin and 
circulation. The levels of proinflammatory cytokines (IL-1, IL-6, TNF-α, etc.) 
have also increased. It is well-known that TNF-α is an important mediator that also 
enhances the synthesis of other proinflammatory cytokines such as IL-1, IL-6, 
and IL-8 [3, 37]. The excellent response of psoriasis to TNF-α inhibitors has been 
emphasized that the role of TNF-α is indisputable in the pathogenesis of psoriasis 
[49]. Another situation demonstrating the effects of current cytokines on hearing 
loss is that TNF-α inhibitor drugs have been used successfully in the treatment of 
SNHL [50, 51]. Ertugrul et al. suggested that the immune response of the inner 
ear in psoriasis is likely to be impaired by antibody response in the endolymphatic 
sac, which has a central role in immunological activity within the inner ear and has 
capable of both processing antigen and producing antibodies [25]. In the case of 
inflammation in the body, accumulation of leukocytes entering the cochlea from 
the peripheral circulation and local immunoglobulin production cause an inflam-
matory reaction. This local inflammation leads to the degeneration of organ of 
corti, stria vascularis and spiral ganglion, which ultimately causes SNHL [32].
High frequency hearing loss in patients with psoriasis and PsA may be associ-
ated with chronic inflammation and autoimmune etiology [14, 15, 19, 21, 23]. It has 
been postulated that comorbidities such as metabolic syndrome and high body mass 
index values, which are frequently accompanied by psoriasis, may also contribute to 
hearing impairment [22]. Comorbid hypertension was determined as independent 
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risk factor for sudden SNHL in psoriasis patients by Yen et al. [12]. In addition, it 
has been suggested that the correlation between high PASI scores and hearing loss 
at medium and high frequencies may be related to the increase of the mediators 
responsible for psoriatic disease to high levels in exacerbation periods [14, 22, 25]. 
However, in most studies, no relationship was found between the duration of 
psoriatic disease, clinical patterns of psoriasis, medical treatments and patient age, 
and hearing loss and/or audiovestibular dysfunction [14–17, 19, 21, 24, 25]. In stud-
ies demonstrating significant hearing loss in psoriasis patients, accompanying joint 
involvement was observed in 5.8% to 51.9% of them [14, 21, 22]. It has been men-
tioned that the presence of joint involvement in patients with psoriasis may lead to 
a more chronic inflammatory process and so adversely affect hearing [25]. Indeed, 
studies evaluating the hearing of psoriasis patients have different results, but it has 
been reported that hearing was adversely affected in all studies examining patients 
with PsA [15, 16, 18, 20]. It has been stated that PsA, which condition facilitates 
additional bone formation, can disrupt outer hair cell integrity through the forma-
tion of autoimmune-mediated fibro-osseous deposits in the cochlea [16].
The main treatment for autoimmune inner ear disease is by corticosteroids, 
and significant improvement of hearing impairment has also been reported in 
previous PsA cases following steroid administration [27–29]. Moreover, promising 
advances have been performed in the treatment of immune-mediated inner ear 
disease with various TNF-α inhibitors (etanercept, infliximab, golimumab; as used 
in other underlying autoimmune diseases or as form of local intratimpanic infu-
sion), demonstrating them to be effective in reducing inflammation and hearing 
loss in cochlear diseases [44, 51]. Nonetheless, if hearing loss still occurs, cochlear 
implantation is a safe and effective method for the auditory rehabilitation of severe 
SNHL [44, 52]. However, flap complications are more common in cases such as 
psoriasis, where the risk of surgical site infection is higher than normal patients. 
It has been beneficial to add perioperative antipsoriatic topical agents and/or UVB 
phototherapy to standard infection prophylaxis in terms of reducing postoperative 
infection and sequelae [52].
4. Conclusion
The relationship between psoriasis/PsA and audiovestibular dysfunction sup-
ports the need for further studies aimed at better identification of the underlying 
pathogenic mechanisms, and accordingly to update diagnostic and even treatment 
approaches. It is well known by most dermatologists that psoriasis is a lifelong 
multisystemic chronic inflammatory disease rather than just a skin and/or joint 
condition. It should also be remembered that psoriatic disease, which has become 
the target of modern biological treatments today, is often accompanied by certain 
comorbidities such as metabolic syndrome, cardiovascular disease and obesity. For 
this reason, psoriasis and its associations should be approached in an integrated 
manner as well as related physicians should be in regular coordination with spe-
cialists in a special multidisciplinary team. However, it is obvious that physicians, 
especially dermatologists and rheumatologists, need to be more aware of the preva-
lence of hearing loss in psoriasis patients. It should be kept in mind that subclinical 
SNHL is a neglected but an important comorbidity in patients with psoriasis and 
PsA. Psoriatic patients, particularly with severe clinical symptoms, arthropathy, 
obesity, hypertension and metabolic syndrome, should be followed up with regular 
audiometric tests even if there is no subjective hearing complaint. In fact, regard-
less of clinical severity or type of psoriasis, evaluation of all psoriatic patients for 
the audiovestibular perspective would be more useful for the future quality of life 
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of patients. If patients with psoriasis have any hearing problem, they should be 
addressed to otorhinolaryngologists and audiometrists in terms of the follow-up to 
possible development of audiovestibular dysfunction and sudden SNHL.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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